Erudio Healtherudio.com
Clinical trial · no report yet · Phase 2
RCT-PAAG trial: what clinicians have said so far
Penpulimab Combined With Anlotinib and Nab-paclitaxel Plus Gemcitabine as First-line Treatment for Advanced Metastatic Pancreatic Cancer
- NCT06051851 ↗
- Unknown
- The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
- Focused size, estimated: 1–150 verified statements once built
We haven't built an HCP commentary report on RCT-PAAG (penpulimab plus anlotinib in first-line metastatic pancreatic adenocarcinoma) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on RCT-PAAG so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Indexed so far | |
|---|---|
| 3 posts on X, typically up to 13 once built |
The trial
ClinicalTrials.gov- Official title
- Penpulimab Combined With Anlotinib and Nab-paclitaxel Plus Gemcitabine (PAAG) as First-line Treatment for Advanced Metastatic Pancreatic Cancer: a Prospective, Multicenter, Single-arm, Phase 2 Study
- Phase
- Phase 2
- Status
- Unknown
- Conditions
- Pancreatic Adenocarcinoma Metastatic
- Interventions
- Penpulimab; Anlotinib; Nab paclitaxel; Gemcitabine
- Arms
- Trial group · Experimental
- Control group · Active comparator
- Enrollment
- 177 (estimated)
- Primary outcomes
- Progression-free survival（PFS）
- Sponsor
- The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
- Start
- Jul 1, 2023
- Primary completion
- Jul 1, 2025 (estimated)
- Results posted
- No
- Registry record
- NCT06051851 · updated Sep 25, 2023